



Diagnósticos da América S.A.

Investor Relations
Av. Juruá, 434 - Alphaville, Barueri - SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT

Diagnósticos da América S.A. Publicly-held Company Corporate Taxpayer's ID (CNPJ/MF) 61.486.650/0001-83

Pursuant to CVM Instruction 358/2002 and applicable legislation, Diagnósticos da América S.A. (Bovespa: DASA3) informs its shareholders and the market that:

On July 19, 2007, Diagnósticos da América S.A. ("DASA") acquired 11,000,000 shares representing 100% of the capital stock of CientificaLab Produtos Laboratoriais e Sistemas S.A. ("CientificaLab"), which provides clinical analysis services to the public healthcare network ("SUS - Sistema Unico de Saúde") in the states of São Paulo, Rio de Janeiro and Minas Gerais.

The shares were acquired for R\$ 85.0 million, of which R\$ 4.0 million represents the net debt position assumed. Of the remaining amount, R\$ 78.0 million will be settled in a single down payment with DASA's own resources and the remaining R\$ 3.0 million will be held in an escrow account for up to 6 years.

An additional earn-out program was developed for the sellers, based on CientificaLab's future revenues. For the period from July 1st, 2007 to June 30th, 2008 the sellers will receive 85% of the incremental gross revenue accrued above R\$ 97.0 million. From 2008 to 2012, the program will consist of annual payments equivalent to 10% of the incremental gross revenue accrued in the previous year.

CientificaLab was founded in 2001, in the city of Barueri (São Paulo), and is the market leader in services to the public market. Since 2003, CientificaLab collects and processes samples for the Public Service Center (PSC) network in the states of São Paulo, Minas Gerais and, more recently, Rio de Janeiro. CientificaLab manages 42 public contracts for the operation of 40 PSCs and the processing of samples for more than 400 public network units. Certified by the SBAC (Brazilian Society of Clinical Analyses) and PELM (Clinical Labs Excellence Program), the laboratory posted gross revenue of R\$ 40.8 million in the first half of 2007.

With the acquisition of CientificaLab, DASA resumes the provision of services to the public healthcare sector, a market in which DASA did not yet have a presence and which now becomes an important growth driver for the Company's strategic plan. The next steps envisage the expansion of CientificaLab to other Brazilian states and municipalities over the upcoming years.

The operation was approved at DASA's Board of Directors Meeting held on July 18, 2007. Given that the acquisition price represents a substantial investment for DASA, pursuant to Article 256, Item I, Paragraph One of Law 6,404/76, the acquisition will be submitted for approval to the Extraordinary Shareholder Meeting, yet to be scheduled. The acquisition of CientificaLab will be submitted to the Brazilian Antitrust Commission (CADE).

Barueri, July 19, 2007

Marcelo Marques Moreira Filho
CEO and Investor Relations Officer